GSK to acquire 25% stake in Aspen Japan
Under the terms of agreement, GSK will buy 25% stake in Aspen Japan, while the remaining 75% stake would be held by Aspen. AGI said in a statement:
Under the terms of agreement, GSK will buy 25% stake in Aspen Japan, while the remaining 75% stake would be held by Aspen. AGI said in a statement:
The companies, along with 12 other global drug manufacturers have received letters from the US House Committee on Oversight and Government Reform Ranking Member Elijah Cummings and Senator
Striverdi Respimat has been prescribed as a once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema The
The rectal foam is a rectally administered corticosteroid that overcomes treatment limitations related with currently approved therapies which are often ineffective due to insufficient distribution of active drug
dCellVax uses the patient’s own immune cells to attack the tumor and its success in the proposed trial is expected to pave the way for expanded use of
Myopic CNV (mCNV) develops in about 5%-10% of patients with pathologic myopia, which is a leading cause of blindness and second only to wet age-related macular degeneration (AMD)
Under the deal, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for tafoxiparin in the US, European, CIS and
ABP 501 is being developed by the company as a biosimilar to adalimumab, an anti-TNF-a monoclonal antibody. The trial evaluated the efficacy and safety of ABP 501 compared
The collaboration builds on two independent research programmes at both the ICR and EMD Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.
The trial is being conducted in Germany for a rare form of bile duct cancer for which currently there is no acceptable therapy. About 200 patients will be